Lidocaine Hydrochloride

2026年5月31日是第39个世界无烟日，今年的主题为“青春无烟，未来无限”。青少年是国家和民族的希望，而烟草正悄然侵蚀着他们的健康根基。在这个特殊的日子里，让我们共同行动起来，为青春护航，为健康发声。 威智医药 以科学之力，守护每一次戒烟决心       作为一家以技术创新为依托的医药健康企业，威智医药始终积极响应国家号召，投身“健康中国”建设。公司历时5年自主研发的戒烟产品——威立戒®（酒石酸伐尼克兰片） ，凭借卓越的科学机理与优异的临床疗效，已成功帮助超过数十万名吸烟者摆脱烟瘾困扰。 Viwit 威立戒®品牌故事       威立戒®的诞生并非一路坦途。从项目立项到最终问世，研发团队经历了常人难以想象的困难：技术路线的反复摸索、实验数据的无数次推翻重来、生产工艺的层层攻关……每一个环节都充满了未知与挑战。但威智人始终没有放弃，他们凭借坚定的信念和扎实的科研精神，一步步攻克难关，将一颗科学、安全、有效的戒烟药带到了患者面前。从实验室的日夜坚守，到生产线上的一丝不苟，再到数十万患者的口碑验证，威立戒®的每一步都凝结着威智人对科学戒烟的执着，以及对患者健康的敬畏！ Viwit 创新，为了更美好的生活  威立戒®的故事，只是威智医药创新版图的一角。自2006年创立于上海以来，威智医药始终秉持 “创新为了更美好的生活” 的企业使命，将技术创新作为企业发展的根本命脉。在“健康中国2030”的时代蓝图下，威智医药坚持以临床需求为导向，持续加大研发投入，致力于为广大人民群众提供更优质、更可及的健康产品与服务。  在第39个世界无烟日到来之际，让我们响应“青春无烟，未来无限”的主题倡议，为自己、为家人、为下一代的健康，勇敢迈出戒烟的坚实一步。威立戒®将始终在戒烟之路上与您同行，用科学的力量，让每一次呼吸都更加清朗，让每一个明天都充满无限可能！ 更多精彩 威智医药荣获京东“创新营销奖”|总裁魏彦君博士受邀出席京东买药 10 周年暨2026京东大药房合作伙伴大会！ 【喜讯】威智医药盐酸利多卡因注射液美国正式获批！ 迈向新征程：威智医药正式启动靶向基因与细胞治疗前沿探索！ 【喜讯】威智医药钆布醇注射液获中国批准上市！ 双星闪耀，品质铸就健康防线 ——威智医药两大产品荣膺2025年“山东制造·鲁链优品”称号！ 创新驱动发展，专注成就“小巨人”，威智医药成功认定第七批国家专精特新“小巨人”企业！

Administering an intravenous drug that contains glass particles could have serious health consequences, and the issue has triggered a number of other product pulls and regulatory wrist slaps in recent years. Generics juggernaut Sun Pharma is pulling one lot of a chemotherapy drug in the United States as the issue of particulate contamination crops up once again on the FDA’s recall register. Sun’s voluntary recall concerns a single batch containing 675 vials of the chemotherapy doxorubicin hydrochloride liposome injection, which is used to treat ovarian cancer, Kaposi sarcoma and multiple myeloma, according to a notice posted on the FDA’s website. The Mumbai-based company is yanking the batch after the discovery of “glass particles in some vials during production.” Administering an intravenous drug that contains the particulates could have serious health consequences, though Sun noted in its May 13 recall notice that it hasn’t received any adverse event reports linked to the suspect lot.Aside from the potential for local irritation and swelling from the presence of foreign material, intravenous injection of glass particles can, in more serious circumstances, block blood vessels and lead to life-threatening clotting, according to Sun’s release. Sun did not provide details on the cause of its glass particle problem, though the company stressed that it has “thoroughly investigated the source” and taken “corrective and preventative actions” in response to the issue. The doxorubicin vials in the affected batch were slated to expire at the end of next May. Glass particles have prompted several recalls over the years, including in Oct. 2023, when Pfizer’s Hospira unit yanked certain sodium bicarbonate and lidocaine HCI injectables over the possible presence of minute bits of glass in product vials. Earlier that same year, GSK recalled two batches of its asthma drug Nucala in Taiwan after glass particles were found in a vial of the drug. GSK had learned of the issue after receiving a complaint from a hospital in Taiwan about the presence of glass particles in one reconstituted vial of the medication. Meanwhile, India’s Zydus in 2024 received an FDA warning letter at its Waghodia plant in Gujarat in part because the company failed to properly root out the source of cross-contamination incidents, including with glass particulates in batches of a product used to treat and prevent a lack of vitamin B12.